Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Incyte Corporation (INCY) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 19,269,900
  • Shares Outstanding, K 188,000
  • Annual Sales, $ 753,750 K
  • Annual Income, $ 6,530 K
  • 36-Month Beta 0.84
  • Price/Sales 24.98
  • Price/Book 50.78

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.01 +22.90%
on 11/04/16
109.95 -7.21%
on 11/09/16
+14.84 (+17.02%)
since 11/02/16
3-Month
77.58 +31.50%
on 09/13/16
109.95 -7.21%
on 11/09/16
+20.00 (+24.38%)
since 09/02/16
52-Week
55.00 +85.49%
on 02/11/16
118.49 -13.90%
on 12/17/15
-11.83 (-10.39%)
since 12/02/15

Most Recent Stories

More News
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

Intellipharmaceutics Submits NDA for Pain Treatment Rexista

Intellipharmaceutics International Inc. (IPCI) announced that it has filed a new drug application (NDA) with the FDA for Rexista.

Merck (MRK) Announces 2.2% Increase in Quarterly Dividend

Merck & Co., Inc, (MRK) recently announced a 2.2% hike in its quarterly dividend.

Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod

Novo Nordisk A/S (NVO) received favorable news with the FDA approving its new drug application for Xultophy 100/3.6.

AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials

AstraZeneca plc (AZN) has resumed enrolment of new patients in head and neck cancer studies of durvalumab as the FDA has lifted a partial clinical hold.

Global Pancreatic Cancer Therapeutics & Diagnostics Market Report 2015-2020 - Analysis, Technologies & Forecasts - Vendors: Amgen, Incyte Corp, Roche - Research and Markets

Research and Markets has announced the addition of the "Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2015-2020)" report to their...

Ligand's Partner Retrophin Provides New Data on Sparsentan

Ligand Pharmaceuticals Incorporated's (LGND) partner Retrophin, Inc. (RTRX) announced additional positive data results from the phase II DUET study

Aduro Reports Partial Hold Lift on LADD Studies in U.S.

The FDA has lifted partial clinical hold that was placed on Aduro Biotech???s (ADRO) LADD-based studies and consequently patient enrollment has resumed.

Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults

Sanofi (SNY) announced that the FDA has approved its once-daily injection, Soliqua 100/33

New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

New Oriental Education & Technology Group, BJ’s Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 107.32
1st Resistance Point 104.67
Last Price 102.02
1st Support Level 98.93
2nd Support Level 95.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.